MICROPORT(00853): Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (688016.SH) is expected to have a net profit attributable to its parent company of 492.5 million to 541 million yuan in 2024, an increase of 0.01% to 9.86% year-on-year.

MICROPORT (00853) announced that Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (688016.SH) is expected to achieve annual operating income of 1.1875 billion to 1.306 billion yuan in 2024, an increase of 0.02% to 10.01% year-on-year. The net profit attributable to owners of the parent company is expected to be 492.5 million to 541 million yuan in 2024, an increase of 0.01% to 9.86% year-on-year. During the reporting period, innovative products from Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., including the Castor branch aortic membrane stent and delivery system, the Minos abdominal aortic membrane stent and delivery system, and the Reewarm PTX drug balloon dilation catheter, continued to perform well. New products such as the Talos straight tube thoracic aortic membrane stent system and the Fontus branch intraoperative stent system saw rapid growth in hospital admissions and terminal implantation volume. However, factors such as price adjustments and promotion strategies, as well as changes in market conditions in the second half of the year, may have an impact on the sales growth and profits for the full year. In the domestic market, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. continued to develop the markets of city-level and county-level hospitals in response to the national policy of continuous decentralization of medical resources. In the international market, the company has been increasing promotion efforts, with overseas sales revenue exceeding 150 million yuan in 2024, further increasing its proportion in the company's revenue. The company is also continuing to promote cooperation with leading customers in the global and regional industries, as well as advancing market access and promotion efforts for aortic and peripheral intervention products in Europe, Latin America, and the Asia-Pacific region. Furthermore, the company is actively promoting pre-market clinical trials for new products in Europe and Japan.